References
- Griffiths PD, Milne R, Emery VC. Human Cytomegalovirus Replication. In: Clinical Virology, 3rd edtion. Richman D, Whitley R, Hayden F (Eds). ASM Press, Washington DC, USA, 475–506 (2008).
- Pawelec G, Derhovanessian E. Role of CMV in immune senescence. Virus Res.157, 175–179 (2011).
- Sylwester AW, Mitchell BL, Edgar JB et al. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J. Exp. Med.202, 673–685 (2005).
- Macagno A, Bernasconi NL, Vanzetta F et al. Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128–131A complex. J. Virol.84, 1005–1013 (2010).
- Hansen SG, Powers CJ, Richards R et al. Evasion of CD8+ T cells is critical for superinfection by cytomegalovirus. Science328, 102–106 (2010).
- Colugnati FA, Staras SA, Dollard SC, Cannon MJ. Incidence of cytomegalovirus infection among the general population and pregnant women in the United States. BMC Infect. Dis.7, 71 (2007).
- Griffiths PD, McLean A, Emery VC. Encouraging prospects for immunisation against primary cytomegalovirus infection. Vaccine19, 1356–1362 (2001).
- Emery VC, Hassan-Walker AF, Burroughs AK, Griffiths PD. Human cytomegalovirus (HCMV) replication dynamics in HCMV-naive and -experienced immunocompromised hosts. J. Infect. Dis.185, 1723–1728 (2002).
- Emery VC, Sabin CA, Cope AV, Gor D, Hassan-Walker AF, Griffiths PD. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet355, 2032–2036 (2000).
- Sung H, Schleiss MR. Update on the current status of cytomegalovirus vaccines. Expert Rev. Vaccines9, 1303–1314 (2010).
- Plotkin SA, Smiley ML, Friedman HM et al. Towne-vaccine-induced prevention of cytomegalovirus disease after renal transplants. Lancet1(8376), 528–530 (1984).
- Plotkin SA, Starr SE, Friedman HM et al. Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant. A controlled trial. Ann. Intern. Med.114(7), 525–531 (1991).
- Pass RF. Development and evidence for efficacy of CMV glycoprotein B vaccine with MF59 adjuvant. J. Clin. Virol.46(Suppl. 4), S73–S76 (2009).
- Pass RF, Zhang C, Evans A et al. Vaccine prevention of maternal cytomegalovirus infection. N. Engl. J. Med.360(12), 1191–1199 (2009).
- Griffiths PD, Stanton A, McCarrell E et al. A Randomised Placebo Controlled Pharmacodynamic Trial of Cytomegalovirus Glycoprotein B Vaccine with MF59 Adjuvant in Transplant Patients. Lancet377, 1256–1263 (2011).
- Wimperis JZ, Brenner MK, Prentice HG et al. Transfer of a functioning humoral immune system in transplantation of T-lymphocyte-depleted bone marrow. Lancet1, 339–343 (1986).
- Wloch MK, Smith LR, Boutsaboualoy S et al. Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects. J. Infect. Dis.197(12), 1634–1642 (2008).
- Bernstein DI, Reap EA, Katen K et al. Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers. Vaccine28(2), 484–493 (2009).
- Barton ES, White DW, Cathelyn JS et al. Herpesvirus latency confers symbiotic protection from bacterial infection. Nature447, 326–329 (2007).
Websites
- Vaccines for the 21st Century: a tool for decisionmaking www.iom.edu/Reports/1999/Vaccines-for-the-21st-Century-A-Tool-for-Decisionmaking.aspx
- TransVax for cytomegalovirus http://www.vical.com/investors/news-releases/News-Release-Details/default.aspx?PressReleaseId=6c77ad12-ccf7-496a-9031-502a06b63f3d
- Vical and Astellas Announce Worldwide License Agreements for TransVax™ Cytomegalovirus Vaccine www.vical.com/investors/news-releases/News-Release-Details/2011/Vical-and-Astellas-Announce-Worldwide-License-Agreements-for-TransVaxTM-Cytomegalovirus-Vaccine1125971/default.aspx